NDA Submission Completed for Zipalertinib + Chemo in 1L EGFR Exon 20 Ins Mutation NSCLC November 18, 2026
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients November 18, 2026
Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy November 18, 2026
Faeth Therapeutics and Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer November 18, 2026
PIVOT-006 Ph 3 Registrational Trial shows RFS Improvement in Intermediate-Risk and High-Grade Ta NMIBC November 18, 2026
CRL Received from FDA for BLA Application Based on HARMONi Study of ivonescimab + platinum-containing chemo for EGFR TKI-treated NSCLC patients November 18, 2026
Natera Announces Clinical Collaboration with Incyte on Interventional Ph 2 Study in CRC November 18, 2026
Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis November 18, 2026
BLA Submission for Detalimogene to be initiated by Year End based on New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC patients November 18, 2026
68% high-grade RFS reported at 12 months in BCG-unresponsive NMIBC study of HIVEC® with mitomycin C November 18, 2026
Positive Preliminary Ph 2 Topline Results Reported from the PIK-201 Trial of PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer November 18, 2026
ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve NMIBC Randomized QUILT-2.005 Trial November 18, 2026
Positive Updated Silevertinib Ph 2 Results Announced with FDA Feedback for Potential Registration path in 1L EGFR-NCM NSCLC November 18, 2026
Quality of Life and Pain Outcomes Data from Ph 3 PANOVA-3 Trial of Tumor Treating Fields for Pancreatic Cancer Published November 18, 2026
Additional Long-Term Follow-Up Data from Ph 2 Study of Safusidenib in IDH1-Mutant Glioma Presented November 18, 2026
Updated interim results from U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT for patients with recurrent GBM announced November 18, 2026
Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for ccRCC Following Treatment With an Anti-PD-1/PD-L1 Therapy November 18, 2026
FDA Accepts sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer November 18, 2026
Not Approvable Letter received from the FDA in response to PMA application for Optune Mya® in NSCLC patients with brain mets following stereotactic radiation November 18, 2026
FDA RMAT and Fast Track Designations for Prizlon-cel in Relapsed or Refractory Large B-Cell Lymphoma November 18, 2026
Perioperative Imfinzi approved in the US in novel regimen with neoadjuvant enfortumab vedotin for patients with MIBC November 18, 2026
FDA approves Wilserdly (giredestrant) for ER-positive, ESR1-mutated advanced breast cancer November 18, 2026